Cargando…

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling

Using a dataset of 150 patients treated with intermittent androgen suppression (IAS) through a fixed treatment schedule, we retrospectively designed a personalized treatment schedule mathematically for each patient. We estimated 100 sets of parameter values for each patient by randomly resampling ea...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirata, Yoshito, Morino, Kai, Akakura, Koichiro, Higano, Celestia S., Aihara, Kazuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805696/
https://www.ncbi.nlm.nih.gov/pubmed/29422657
http://dx.doi.org/10.1038/s41598-018-20788-1
_version_ 1783299005656072192
author Hirata, Yoshito
Morino, Kai
Akakura, Koichiro
Higano, Celestia S.
Aihara, Kazuyuki
author_facet Hirata, Yoshito
Morino, Kai
Akakura, Koichiro
Higano, Celestia S.
Aihara, Kazuyuki
author_sort Hirata, Yoshito
collection PubMed
description Using a dataset of 150 patients treated with intermittent androgen suppression (IAS) through a fixed treatment schedule, we retrospectively designed a personalized treatment schedule mathematically for each patient. We estimated 100 sets of parameter values for each patient by randomly resampling each patient’s time points to take into account the uncertainty for observations of prostate specific antigen (PSA). Then, we identified 3 types and classified patients accordingly: in type (i), the relapse, namely the divergence of PSA, can be prevented by IAS; in type (ii), the relapse can be delayed by IAS later than by continuous androgen suppression (CAS); in type (iii) IAS was not beneficial and therefore CAS would have been more appropriate in the long run. Moreover, we obtained a treatment schedule of hormone therapy by minimizing the PSA of 3 years later in the worst case scenario among the 100 parameter sets by searching exhaustively all over the possible treatment schedules. If the most frequent type among 100 sets was type (i), the maximal PSA tended to be kept less than 100 ng/ml longer in IAS than in CAS, while there was no statistical difference for the other cases. Thus, mathematically personalized IAS should be studied prospectively.
format Online
Article
Text
id pubmed-5805696
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-58056962018-02-16 Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling Hirata, Yoshito Morino, Kai Akakura, Koichiro Higano, Celestia S. Aihara, Kazuyuki Sci Rep Article Using a dataset of 150 patients treated with intermittent androgen suppression (IAS) through a fixed treatment schedule, we retrospectively designed a personalized treatment schedule mathematically for each patient. We estimated 100 sets of parameter values for each patient by randomly resampling each patient’s time points to take into account the uncertainty for observations of prostate specific antigen (PSA). Then, we identified 3 types and classified patients accordingly: in type (i), the relapse, namely the divergence of PSA, can be prevented by IAS; in type (ii), the relapse can be delayed by IAS later than by continuous androgen suppression (CAS); in type (iii) IAS was not beneficial and therefore CAS would have been more appropriate in the long run. Moreover, we obtained a treatment schedule of hormone therapy by minimizing the PSA of 3 years later in the worst case scenario among the 100 parameter sets by searching exhaustively all over the possible treatment schedules. If the most frequent type among 100 sets was type (i), the maximal PSA tended to be kept less than 100 ng/ml longer in IAS than in CAS, while there was no statistical difference for the other cases. Thus, mathematically personalized IAS should be studied prospectively. Nature Publishing Group UK 2018-02-08 /pmc/articles/PMC5805696/ /pubmed/29422657 http://dx.doi.org/10.1038/s41598-018-20788-1 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Hirata, Yoshito
Morino, Kai
Akakura, Koichiro
Higano, Celestia S.
Aihara, Kazuyuki
Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
title Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
title_full Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
title_fullStr Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
title_full_unstemmed Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
title_short Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
title_sort personalizing androgen suppression for prostate cancer using mathematical modeling
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805696/
https://www.ncbi.nlm.nih.gov/pubmed/29422657
http://dx.doi.org/10.1038/s41598-018-20788-1
work_keys_str_mv AT hiratayoshito personalizingandrogensuppressionforprostatecancerusingmathematicalmodeling
AT morinokai personalizingandrogensuppressionforprostatecancerusingmathematicalmodeling
AT akakurakoichiro personalizingandrogensuppressionforprostatecancerusingmathematicalmodeling
AT higanocelestias personalizingandrogensuppressionforprostatecancerusingmathematicalmodeling
AT aiharakazuyuki personalizingandrogensuppressionforprostatecancerusingmathematicalmodeling